Haemonetics (HAE) Stock Forecast & Price Target

HAE price $120.04 +1.72 +1.45%

Ticker
HAE
Price
$120.04
Change
+1.72 +1.45%
Market cap ?
$5.46B
P/E ?
57.44
Forward P/E ?
22.59
Dividend yield ?
0.00%
Beta ?
0.54
Sector
Healthcare
Industry
Medical - Devices
Stocklytics score
50
Value
37
Quality
63
Growth
51

Stocklytics score rationale: value 37, quality 63, growth 51.

Financials

2017201820192020202120222023202420252026
8861160009039230009675790009884790008704630009931960001168660000130905500013608240001334027000

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated…

Fair value

HAE fair value $153.64. Price $120.04. Price is 22% below fair value.

Above fair value, but less expensive than usual. A smaller premium than on 64% of days in the past 5 years.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 291.22M. Growth 8.63%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 45.50M. Net debt 979.14M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Compare HAE

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-05—1.29—345.15M
2026-08-061.141.08339.38M327.86M
2026-05-071.291.28346.35M336.83M
2026-02-051.311.27339.00M331.92M
2025-11-061.271.12327.31M329.77M
2025-08-071.101.01321.39M320.01M
2025-05-081.241.22330.60M312.47M
2025-02-061.191.18348.54M354.46M
2024-11-071.121.09345.51M342.65M
2024-08-081.021.03336.17M335.38M
2024-05-090.900.88343.29M329.11M
2024-02-081.040.97336.25M320.29M
2023-11-020.990.94318.18M313.12M
2023-08-081.050.73311.33M292.69M
2023-05-110.770.68304.42M289.64M
2023-02-070.850.79305.30M299.56M
2022-11-070.830.67297.49M269.22M
2022-08-100.580.53261.46M249.00M
2022-05-100.650.60265.00M257.11M
2022-02-080.840.75259.77M265.39M
2021-11-090.600.63239.90M239.99M
2021-08-110.500.47228.53M228.53M
2021-05-130.460.67225.03M223.05M
2021-02-020.810.65240.37M181.20M
2020-11-040.620.50209.49M11.44M
2020-08-040.460.41195.58M174.32M
2020-05-050.690.73238.49M252.32M
2020-02-040.940.76258.97M209.38M
2019-11-010.870.69252.57M203.21M
2019-08-060.810.63238.45M185.46M
2019-05-070.610.55249.29M224.77M
2019-02-050.630.59247.36M231.65M
2018-11-060.560.54241.58M232.97M
2018-08-070.590.42229.35M163.23M
2018-05-080.430.43233.55M228.17M
2018-02-060.620.44234.04M166.06M
2017-11-070.480.41225.38M192.53M
2017-08-070.330.31210.95M198.21M
2017-05-080.390.37228.07M222.25M
2017-02-060.430.40227.84M217.20M

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-07-24Madaus Martin DBuy2.54K——
2026-07-24Zane Ellen MBuy2.54K——
2026-07-24Pomeroy ClaireBuy2.54K——
2026-07-24KROLL MARK WBuy2.54K——
2026-07-24Johnson Lloyd EmersonBuy2.54K——
2026-07-24COYLE MICHAEL JBuy2.54K——
2026-07-24Bryant Diane MBuy2.54K——
2026-07-24ABERNATHY ROBERT EBuy2.54K——
2026-07-24Madaus Martin DOther0——
2026-06-05Maunsell Farris MaryanneSell259$71.2818.46K
2026-06-05Miller Laurie A.Sell313$71.2822.31K
2026-05-15Basil Michelle LBuy28.42K——
2026-05-15Basil Michelle LSell2.91K$56.29163.97K
2026-05-15Chan FrankBuy27.54K——
2026-05-15Chan FrankSell546$56.2930.73K
2026-05-15DArecca JamesBuy29.31K——
2026-05-15DArecca JamesSell2.50K$56.29141.01K
2026-05-15Maunsell Farris MaryanneBuy2.22K——
2026-05-15Maunsell Farris MaryanneSell197$56.2911.09K
2026-05-15Galvin RoyBuy27.54K——
2026-05-15Galvin RoySell879$56.2949.48K
2026-05-15Miller Laurie A.Buy13.32K——
2026-05-15Miller Laurie A.Sell948$56.2953.36K
2026-05-15Simon, ChristopherBuy78.34K——
2026-05-15Simon, ChristopherSell9.68K$56.29544.94K
2026-05-01DArecca JamesSell655$59.2638.82K
2025-11-10KROLL MARK WBuy1.40K$70.5698.78K
2025-10-31Galvin RoySell145$50.017.25K
2025-09-17Miller Laurie A.Sell238$49.9511.89K
2025-07-24Zane Ellen MBuy2.69K——
2025-07-24Pomeroy ClaireBuy2.69K——
2025-07-24KROLL MARK WBuy2.69K——
2025-07-24Johnson Lloyd EmersonBuy2.69K——
2025-07-24Dockendorff Charles JBuy2.69K——
2025-07-24COYLE MICHAEL JBuy2.69K——
2025-07-24Bryant Diane MBuy2.69K——
2025-07-24ABERNATHY ROBERT EBuy2.69K——
2025-06-05Miller Laurie A.Buy3.19K——
2025-06-05Maunsell Farris MaryanneBuy2.66K——
2025-05-30Simon, ChristopherBuy66.67K——
2025-05-30Simon, ChristopherSell26.23K$69.381.82M
2025-05-30Miller Laurie A.Buy7.78K——
2025-05-30Miller Laurie A.Sell2.28K$69.38158.39K
2025-05-30DArecca JamesBuy12.22K——
2025-05-30DArecca JamesSell5.86K$69.38406.84K
2025-05-30Basil Michelle LBuy15.55K——
2025-05-30Basil Michelle LSell7.47K$69.38518.20K
2025-05-16Basil Michelle LBuy6.75K——
2025-05-16Basil Michelle LBuy14.63K$70.311.03M
2025-05-16Galvin RoyBuy5.69K——
2025-05-16Galvin RoyBuy12.32K$70.31866.01K
2025-05-16Maunsell Farris MaryanneBuy800——
2025-05-16Maunsell Farris MaryanneBuy1.73K$70.31121.78K
2025-05-16Miller Laurie A.Buy3.20K——
2025-05-16Miller Laurie A.Buy6.93K$70.31487.11K
2025-05-16Chan FrankBuy12.32K$70.31866.01K
2025-05-16Chan FrankBuy5.69K——
2025-05-16Galvin RoyBuy14.63K$70.311.03M
2025-05-16Galvin RoyBuy6.75K——
2025-05-16Basil Michelle LBuy5.69K——
2025-05-16Basil Michelle LBuy12.32K$70.31866.01K
2025-05-16DArecca JamesBuy7.11K——
2025-05-16DArecca JamesBuy15.40K$70.311.08M
2025-05-16Simon, ChristopherBuy21.41K——
2025-05-16Simon, ChristopherBuy46.34K$70.313.26M
2025-05-16Basil Michelle LSell2.16K$70.31151.66K
2025-05-16DArecca JamesSell1.25K$70.3187.61K
2025-05-16Maunsell Farris MaryanneSell68$70.314.78K
2025-05-16Galvin RoySell257$70.3118.07K
2025-05-16Miller Laurie A.Sell477$70.3133.54K
2025-05-16Simon, ChristopherSell7.09K$70.31498.43K
2025-05-15Basil Michelle LSell622$69.3843.15K
2025-05-15DArecca JamesSell622$69.3843.15K
2025-05-15Maunsell Farris MaryanneSell60$69.384.16K
2025-05-15Galvin RoySell201$69.3813.95K
2025-05-15Miller Laurie A.Sell206$69.3814.29K
2025-05-15Simon, ChristopherSell2.39K$69.38165.89K
2025-05-02DArecca JamesSell654$63.8541.76K
2025-04-07Chan FrankOther0——
2024-11-01Galvin RoySell161$71.4811.51K
2024-09-17Miller Laurie A.Sell238$76.5418.22K
2024-08-29Simon, ChristopherSell39.70K$75.563.00M
2024-07-26Strong Stewart WSell4.31K$91.15393.04K
2024-07-25Strong Stewart WSell2.80K$90.58253.44K
2024-07-25ABERNATHY ROBERT EBuy2.21K——
2024-07-25Bryant Diane MBuy2.21K——
2024-07-25COYLE MICHAEL JBuy2.21K——
2024-07-25Dockendorff Charles JBuy2.21K——
2024-07-25Johnson Lloyd EmersonBuy2.21K——
2024-07-25KROLL MARK WBuy2.21K——
2024-07-25Pomeroy ClaireBuy2.21K——
2024-07-25Zane Ellen MBuy2.21K——
2024-07-24Strong Stewart WBuy7.11K——
2024-07-12Lingamneni AnilaSell79$90.007.11K
2024-07-11Lingamneni AnilaSell2.14K$90.00192.24K
2024-06-06Simon, ChristopherBuy104.52K$41.644.35M
2024-06-06Simon, ChristopherSell71.33K$87.386.23M
2024-06-06Simon, ChristopherSell104.52K$41.644.35M
2024-05-29Basil Michelle LSell8.90K$87.86781.60K
2024-05-29Basil Michelle LSell4.09K$88.57362.61K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 343, holders +11 vs prior quarter. Ownership 108.75%.

HolderSharesChangeChange %Value
BLACKROCK, INC.5.91M289.28K+5.15%443.19M
NEUBERGER BERMAN GROUP LLC4.18M618.52K+17.37%313.47M
VANGUARD PORTFOLIO MANAGEMENT LLC2.55M-12.92K-0.50%190.98M
AQR CAPITAL MANAGEMENT LLC2.27M-1.09M-32.48%165.02M
ARIEL INVESTMENTS, LLC2.06M2.06MNew154.57M
VANGUARD CAPITAL MANAGEMENT LLC2.06M-30.81K-1.47%154.47M
STATE STREET CORP1.82M45.29K+2.55%136.36M
DIMENSIONAL FUND ADVISORS LP1.59M259.17K+19.54%118.89M
CITADEL ADVISORS LLC1.51M1.25M+484.97%113.26M
GEODE CAPITAL MANAGEMENT, LLC1.29M68.26K+5.60%96.56M
RIVER ROAD ASSET MANAGEMENT, LLC1.29M-42.39K-3.19%96.42M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP1.16M-227.65K-16.46%86.65M
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.1.10M504.22K+84.44%82.60M
GOLDMAN SACHS GROUP INC1.05M93.20K+9.78%78.45M
UBS GROUP AG983.38K456.76K+86.73%73.75M
FORT WASHINGTON INVESTMENT ADVISORS INC /OH/830.92K-10.09K-1.20%62.32M
ROYAL BANK OF CANADA780.25K-77.72K-9.06%58.52M
ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC765.12K-125.10K-14.05%57.27M
PRICE T ROWE ASSOCIATES INC /MD/636.80K216.52K+51.52%47.76M
DEUTSCHE BANK AG\631.66K272.78K+76.01%47.37M
NORTHERN TRUST CORP631.54K52.24K+9.02%47.37M
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.591.42K591.42KNew44.36M
CHARLES SCHWAB INVESTMENT MANAGEMENT INC591.42K19.32K+3.38%44.36M
BOSTON TRUST WALDEN CORP585.15K83.26K+16.59%43.89M
MILLENNIUM MANAGEMENT LLC570.41K570.41KNew42.78M

Forecast

Consensus Buy from 11 analysts. Average price target $130.80, +9.0% versus the current price. Low $119.00. High $140.00.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Analysts have an average 12-month price target of $130.80 for Haemonetics (HAE), 8.7% above the current price of $120.35. Of 11 analysts covering the stock, 9 rate it Buy or Strong Buy, 2 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.

Forecasts are third-party estimates and often wrong. They are not investment advice.

HAE price target

12-month price target
Low$119.00
Average$130.80
High$140.00

The average is 8.7% above the current price of $120.35.

Is Haemonetics a buy or sell?

Of 11 analysts, 9 rate Haemonetics Buy or Strong Buy, 2 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.

Haemonetics earnings and revenue forecast

Analyst averages on file: 2026, EPS $4.94, revenue $1.33 billion. 2027, EPS $5.31, revenue $1.42 billion.

HAE score and fair value

The Stocklytics Score for HAE is 50 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.

HAE forecast FAQs

What is the HAE price target?

$130.80 average, with a published range of $119.00 to $140.00.

Is Haemonetics a buy or sell?

The consensus is Buy from 11 analysts. This is not a recommendation.

What is the Haemonetics stock forecast for 2026?

Analysts' average EPS estimate for 2026 on file is $4.94. The average revenue estimate is $1.33 billion.

What will HAE be worth in 2030?

No reliable forecast exists that far out.

When is Haemonetics's next earnings report?

The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.

Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.

Haemonetics (HAE) Stock Forecast & Price Target

HAE$120.04+1.72 +1.45%

$5.46B

Market Cap

57.44

P/E

22.59

Forward P/E

50

Score

Price History